Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes.
The natural polyamines are ubiquitous polycationic compounds that play important biological functions in cell growth and differentiation. In the case of protozoan species that are causative agents of important human diseases such as Leishmaniasis, an exogenous supply of polyamines supports parasite proliferation. In the present study, we have investigated the effect of three polyamine derivatives, (namely bis-naphthalimidopropyl putrescine (BNIPPut), spermidine (BNIPSpd) and spermine (BNIPSpm)), on the proliferative stages of Leishmania infantum, the causative agent of visceral leishmaniasis in the Mediterranean basin. A significant reduction of promastigotes and axenic amastigotes growth was observed in the presence of increasing concentrations of the drugs, although the mechanisms leading to the parasite growth arrest seems to be different. Indeed, by using a number of biochemical approaches to analyse the alterations that occurred during early stages of parasite-drug interaction (i.e. membrane phosphatidylserine exposure measured by annexin V binding, DNA fragmentation, deoxynucleotidyltranferase-mediated dUTP end labelin (TUNEL), mitochondrial transmembrane potential loss), we showed that the drugs had the capacity to induce the death of promastigotes by a mechanism that shares many features with metazoan apoptosis. Surprisingly, the amastigotes did not behave in a similar way to promastigotes. The drug inhibitory effect on amastigotes growth and the absence of propidium iodide labelling may suggest that the compounds are acting as cytostatic substances. Although, the mechanisms of action of these compounds have yet to be elucidated, the above data show for the first time that polyamine derivatives may act differentially on the Leishmania parasite stages. Further chemical modifications are needed to make the polyamine derivatives as well as other analogues able to target the amastigote stage of the parasite.
Tavares
J
J
Laboratório de Bioquímica, Faculdade de Farmácia da Universidade do Porto, Portugal.
Ouaissi
A
A
Lin
P K T
PK
Tomás
A
A
Cordeiro-da-Silva
A
A
D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015317:Biogenic Polyamines / Q000494:pharmacology*; D053938:DNA Fragmentation / Q000187:drug effects; D016054:DNA, Protozoan / Q000187:drug effects; D005434:Flow Cytometry / Q000379:methods; D005455:Fluorescent Antibody Technique / Q000379:methods; D020287:In Situ Nick-End Labeling / Q000379:methods; D018314:Leishmania infantum / Q000187:drug effects* / Q000254:growth & development; D008564:Membrane Potentials / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects; D010539:Permeability / Q000187:drug effects; D010718:Phosphatidylserines / Q000378:metabolism; D011700:Putrescine / Q000031:analogs & derivatives / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D013095:Spermidine / Q000031:analogs & derivatives / Q000494:pharmacology; D013096:Spermine / Q000031:analogs & derivatives / Q000494:pharmacology
D000977:Antiparasitic Agents; D015317:Biogenic Polyamines; D016054:DNA, Protozoan; D010718:Phosphatidylserines; D015363:Quinolones; C504603:bisnaphthalimidopropyl putrescine; C504604:bisnaphthalimidopropyl spermine; C439296:bisnaphthalimidopropylspermidine; D013096:Spermine; D013095:Spermidine; D011700:Putrescine